Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The World Health Organization (WHO) recently added snakebite envenoming to the priority list of Neglected Tropical Diseases (NTD). It is thought that ~75% of mortality following snakebite occurs outside the hospital setting, making the temporal gap between a bite and antivenom administration a major therapeutic challenge. Small molecule therapeutics (SMTs) have been proposed as potential prereferral treatments for snakebite to help address this gap. Herein, we discuss the characteristics, potential uses, and development of SMTs as potential treatments for snakebite envenomation. We focus on SMTs that are secretory phospholipase A2 (sPLA 2) inhibitors with brief exploration of other potential drug targets on venom molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Snake Venom PLA 2 , a Promising Target for Broad-Spectrum Antivenom Drug Development
Xiao, H., Pan, H., Liao, K., Yang, M., & Huang, C. (2017) · BioMed Research International · doi:10.1155/2017/6592820 · Cited by 113
Secretory phospholipase A2 predicts impending acute chest syndrome in sickle cell disease
Styles, L. A., Aarsman, A. J., Vichinsky, E. P., & Kuypers, F. A. (2000) · Blood · doi:10.1182/blood.v96.9.3276 · Cited by 105
Toxin synergism in snake venoms
Laustsen, A. H. (2016) · Toxin Reviews · doi:10.1080/15569543.2016.1220397 · Cited by 65 · cited 4×
“The use of tools, such as the newly developed Toxicity Score, which combines the medical importance and the relative abundance of a specific toxin, can aid the identification of a target [34, 35].”
BackgroundMethodInfluential
Cited by
Causes and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396
Gutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92
“In this regard, the search for inhibitors that have been developed for diseases whose pathogenesis is associated with endogenous enzymes, such as PLA2s and metalloproteinases, represents a potentially cost- and development time-efficient piggy-back approach by taking advantage of previous preclinical and clinical asse…”
BackgroundSelf-citationHall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
“…bene fi t for tackling snake-bite morbidity, both oral and transdermal delivery methods share the bene fi t of being amenable for rapid administration in the community soonafterasnakebiteoccurs,andwellbeforeapatientcouldcurrently reach hospital for IV-administration of antivenom 9,31,32,35,37 – 39 .”
InfluentialXie, C., Albulescu, L.-O., Still, K. B. M., Slagboom, J., Zhao, Y., Jiang, Z., Somsen, G. W., Vonk, F. J., Casewell, N. R., & Kool, J. (2020) · Biomedicines · doi:10.3390/biomedicines8060165 · Cited by 58
“Small molecule toxin inhibitor‐based approaches are gaining much traction as promising alternatives and/or complementary treatments for snakebite [12–16], as they show a number of characteristics desirable for use as either early prehospital or adjunct therapies [13].”
Background
Metadata
- Authors
- Bulfone, T. C., Samuel, S. P., Bickler, P. E., & Lewin, M. R.
- Venue
- Journal of Tropical Medicine
- Publisher
- Wiley
- Published
- 2018-07-30
- Volume
- 2018
- Pages
- 1-10
- ISSN
- 1687-9686 (ISSN-L)
- 1687-9694
- OpenAlex
- W2885567997
- Cited by
- 83
- References
- 4
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite. https://app.cochat.ai/papers/10.1155/2018/4320175
- The paper
- Bulfone, T. C., Samuel, S. P., Bickler, P. E., & Lewin, M. R. (2018). Developing Small Molecule Therapeutics for the Initial and Adjunctive Treatment of Snakebite. Journal of Tropical Medicine. https://doi.org/10.1155/2018/4320175
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.